NUMELVI™ (atinvicitinib tablets) is the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older.
The product is expected to be available at veterinary clinics and hospitals nationwide in spring 2026.
Source: Merck Animal Health, February 27, 2026. Link.
NUMELVI also offers added convenience for veterinary clinics; most dogs, starting at weights as low as 4.4 pounds, require only one or half of a tablet, and there is no need to adjust vaccination schedules.” – Christine McKinney, DVM, DACVD
Leave a Reply